دورية أكاديمية

Design, Rationale and Initial Findings From HERA‐FIB on 10 222 Patients With Atrial Fibrillation Presenting to an Emergency Department Over An 11‐Year Period

التفاصيل البيبلوغرافية
العنوان: Design, Rationale and Initial Findings From HERA‐FIB on 10 222 Patients With Atrial Fibrillation Presenting to an Emergency Department Over An 11‐Year Period
المؤلفون: Christian Salbach, Mustafa Yildirim, Hauke Hund, Moritz Biener, Matthias Müller‐Hennessen, Norbert Frey, Hugo A. Katus, Evangelos Giannitsis, Barbara Ruth Milles
المصدر: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024)
بيانات النشر: Wiley, 2024.
سنة النشر: 2024
المجموعة: LCC:Diseases of the circulatory (Cardiovascular) system
مصطلحات موضوعية: atrial fibrillation, non–vitamin K oral anticoagulant, real‐world evidence, registry, vitamin K antagonist, Diseases of the circulatory (Cardiovascular) system, RC666-701
الوصف: Background For the majority of patients with atrial fibrillation (AF), disease management has improved in recent years. However, there are still populations underrepresented or excluded in current registries and randomized controlled trials. HERA‐FIB (Heidelberg Registry of Atrial Fibrillation) was planned to assess real‐world evidence for the prevalence, demographic characteristics and management of patients with the diagnosis of AF presenting consecutively to a chest pain unit. Methods and Results HERA‐FIB is a retrospective, observational, single‐center study on patients with a diagnosis of AF presenting to a chest pain unit from June 2009 until March 2020. This article describes the structure, governance, outcome assessment, quality and data collection processes of the registry. Additionally, characteristics of populations of special interest are described. The study consecutively enrolled 10 222 patients presenting with AF to the chest pain unit of the University Hospital of Heidelberg. Clinical parameters and patient characteristics were assessed retrospectively. Outcome parameters included rates for all‐cause death, stroke, myocardial infarction and major bleedings. We were able to investigate patient cohorts of special interest such as advanced chronic kidney disease, octogenarians, and those with acute coronary syndrome who are often underrepresented in current studies and randomized controlled trials. Conclusions HERA‐FIB is one of the largest real‐world single‐center retrospective registries on patients with AF, which captures the era of transition from vitamin K antagonists to non–vitamin K oral anticoagulation regimens in clinical practice and offers the possibility to investigate patient populations usually underrepresented or excluded in current available randomized controlled trials and registries. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT05995561.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2047-9980
Relation: https://doaj.org/toc/2047-9980
DOI: 10.1161/JAHA.123.033396
URL الوصول: https://doaj.org/article/14b8d1d4d4d8403b9f1a7f9714ac03da
رقم الأكسشن: edsdoj.14b8d1d4d4d8403b9f1a7f9714ac03da
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20479980
DOI:10.1161/JAHA.123.033396